feed,title,long_url,short_url
Benzinga,Here's How Much You Would Have Made Owning Axon Enterprise Stock In The Last 5 Years,https://benzinga.com/insights/news/24/09/40963285/heres-how-much-you-would-have-made-owning-axon-enterprise-stock-in-the-last-5-years,https://da.gd/Rqg81l
Benzinga,Here's How Much $100 Invested In Autodesk 10 Years Ago Would Be Worth Today,https://benzinga.com/insights/news/24/09/40963275/heres-how-much-100-invested-in-autodesk-10-years-ago-would-be-worth-today,https://da.gd/hFqTPu
Benzinga,Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients,https://benzinga.com/general/biotech/24/09/40963255/johnson-johnsons-rybrevant-scores-third-fda-approval-of-2024-for-certain-type-of-inoperable-lung-,https://da.gd/M9OJJf
Benzinga,What's Going On With NovaBay Pharmaceuticals Shares Friday?,https://benzinga.com/news/24/09/40963246/whats-going-on-with-novabay-pharmaceuticals-shares-friday,https://da.gd/W00q5
Benzinga,Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease,https://benzinga.com/general/biotech/24/09/40963228/zevra-therapeutics-drug-becomes-first-fda-approved-treatment-for-ultra-rare-neurodegenerative-dis,https://da.gd/nEA42F
